Drug updated on 4/17/2024
| Dosage Form | Tablet (oral; 15 mg, 30 mg, 45 mg, 60 mg and 90 mg) |
| Drug Class | Selective vasopressin V2-receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
Summary
- Tolvaptan (Jynarque) is a drug indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
- A meta-analysis found that compared with placebo, tolvaptan had a better effect on delaying eGFR decline and TKV increase in ADPKD treatment.
- The same study also showed that Jynarque reduced the incidence of complications such as renal pain, urinary tract infection, haematuria, and hypertension in patients with ADPKD.
- However, it was noted that tolvaptan was associated with a higher incidence rate of adverse events such as thirst, polyuria and hepatic injury.
- Another systematic review evaluated the efficacy and safety outcomes of using Jynarque for heart failure management in patients with chronic kidney disease (CKD). It concluded that its safety profile appears acceptable for these patients without deterioration in renal function but further research is needed for long-term benefits assessment.
- These findings are based on two Systematic Reviews / Meta-Analyses documents related specifically to the use of Tolvaptan (Jynarque) within specific patient populations suffering from either ADPKD or CKD combined with HF conditions respectively.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Jynarque (tolvaptan) Prescribing Information. | 2020 | Otsuka America Pharmaceutical, Inc., Rockville, MD |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis. | 2022 | International Urology and Nephrology |
| Tolvaptan for heart failure in chronic kidney disease patients: a systematic review and meta-analysis. | 2018 | Heart Lung and Circulation |